The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).
 
Gilbert Youssef
No Relationships to Disclose
 
Justin Lathia
Employment - Cleveland Clinic
 
Eudocia Quant Lee
Honoraria - Medlink
Consulting or Advisory Role - Medscape
Patents, Royalties, Other Intellectual Property - Royalties from Wolter Kluwer for Up to Date, Inc
 
Ugonma Nnenna Chukwueke
Stock and Other Ownership Interests - Abbott Laboratories (I); Abbvie (I); Becton Dickinson (I); Danaher (I); Johnson and Johnson (I); Medtronic (I); Novartis (I)
 
Adam Lauko
Employment - Cleveland Clinic
 
Tracy Batchelor
Research Funding - Ono Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Oxford University Press; UpToDate
 
Elisa Aquilanti
Employment - Dana-Farber Cancer Institute
 
Lakshmi Nayak
Honoraria - Ono Pharmaceutical
Consulting or Advisory Role - BraveBio; Genmab; Kite/Gilead; Ono Pharmaceutical
Speakers' Bureau - Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Kazia Therapeutics (Inst); Merck (Inst); Ono Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer/ UpToDate, Inc- Royalty
Travel, Accommodations, Expenses - Ono Pharmaceutical
 
Alexa Myers
Employment - Dana-Farber Cancer Institute
 
Alyssa Russ
No Relationships to Disclose
 
Catharina C Westergaard
Employment - Dana-Farber Cancer Institute
 
Tyler Alban
Employment - Cleveland Clinic
 
Jakub Jarmula
Employment - Cleveland Clinic
 
Juyeun Lee
Employment - Cleveland Clinic
 
Michael A. Vogelbaum
Stock and Other Ownership Interests - Infusion Therapeutics
Consulting or Advisory Role - Midatech Pharma; Olympus; SERVIER
Research Funding - Celgene (Inst); Denovo Biopharma (Inst); Infusion Therapeutics (Inst); Oncosynergy (Inst)
Patents, Royalties, Other Intellectual Property - Patent for drug delivery devices, assigned to Moffitt Cancer Center.; Patents for drug delivery devices for the brain
 
Kazuko Matsuda
Employment - Medicinova
Leadership - Medicinova
Consulting or Advisory Role - Medicinova
 
David A. Reardon
Stock and Other Ownership Interests - Anheart Therapeutics; Bionaut Labs
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Avita Biomedical, Inc.; Bayer; Blue Rock Therapeutics; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CeCaVa; Chimeric Therapeutics; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Genentech/Roche; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; Monteris Medical; NEUVOGEN; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Avita Biomedical; Bayer; Blue Rock Therapeutics; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CeCava; Chimeric Therapeutics; Deciphera; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Genentech/Roche; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Sumitomo Dainippon Pharma Oncology; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Asvattha Therapeutics (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); InSightec (Inst); Merck (Inst); NeoTX (Inst); Novartis (Inst); Omniox
 
Patrick Y. Wen
Consulting or Advisory Role - Anheart Therapeutics; AstraZeneca; Bayer; Black Diamond Therapeutics; Boehringer Ingelheim; Celularity; Chimerix; Day One Biopharmaceuticals; Genenta Science; GlaxoSmithKline; Insightec; Kintara Therapeutics; Merck; Mundipharma; Mundipharma; Novartis; Novocure; Novocure; Prelude Therapeutics; Prelude Therapeutics; Sagimet Biosciences; Sapience Therapeutics; Servier; Servier; SymBio Pharmaceuticals; Tango Therapeutics; Telix Pharmaceuticals; VBI Vaccines
Research Funding - AstraZeneca (Inst); Bayer (Inst); Black Damond (Inst); Chimerix (Inst); Erasca, Inc (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Quadriga Biosciences (Inst); Servier (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)